ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Efficacy of sequential romosozumab-denosumab therapy in patients on hemodialysis: association with bone mineral density improvement and TRACP-5b rebound.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis treatment in patients undergoing maintenance dialysis remains to be established. Sequential romosozumab-to-denosumab therapy improved bone mineral density and suppressed bone turnover. Shorter transition periods were associated with reduced TRACP-5b rebound, highlighting the importance of transition management and suggesting this approach as a promising option for this high-risk population. PURPOSE: Patients on dialysis have a higher risk of fractures than the general population. However, osteoporosis treatment in patients on dialysis has not been established. We aimed to evaluate the efficacy of sequential therapy with romosozumab followed by denosumab and examine the clinical impact of the transition period between these agents.
methodsIn this retrospective multicenter cohort study, 34 patients on maintenance dialysis received romosozumab for 12 months followed by denosumab for 12 months. Endpoints included lumbar spine and femoral neck bone mineral density and bone turnover marker levels. The transition period between the two agents was analyzed in relation to rebound of tartrate-resistant acid phosphatase 5b level.
resultsSequential therapy improved bone mineral density (lumbar spine: 0.797-0.997 g/cm²; femoral neck: 0.490-0.537 g/cm² p < 0.001) and the corresponding T-scores (lumbar spine: -2.1 to -0.9; femoral neck: -3.0 to -2.7; p < 0.001). Bone turnover marker levels also improved, including a marked decrease in tartrate-resistant acid phosphatase 5b levels. However, as both agents may induce hypocalcemia, we implemented an internal protocol involving strict monitoring of parathyroid hormone and serum calcium levels. Consequently, some patients required a longer interval before transitioning from romosozumab to denosumab. A longer transition period was associated with greater rebound of tartrate-resistant acid phosphatase 5b level, particularly when the interval exceeded 4 months.
conclusionThe sequential therapy was associated with significant improvements in bone mineral density and bone turnover marker levels among patients on dialysis. Timely transition between agents appears critical to maintain suppression of bone resorption.
Indexed as
Identifiers
42821093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.